Post-Traumatic Stress Disorder Clinical Trial
Official title:
PET Evaluation of NK1 Receptor Using [18F]SPA-RQ in Post-Traumatic Stress Disorder
This study will examine the role of substance P, a chemical messenger in the brain, in
post-traumatic stress disorder (PTSD), a chronic anxiety disorder. PTSD can develop after
exposure to a terrifying event or ordeal, such as a violent personal assault, natural or
human-caused disaster, accident, or military combat. Substance P is a peptide that may be
important in the response to certain psychiatric and neurological diseases and conditions,
including anxiety.
Healthy normal volunteers and people with PTSD who are between 18 and 65 years of age may be
eligible for this study. Candidates are screened with a physical examination, blood and
urine tests, pregnancy test for women who can become pregnant, and a neuropsychological
evaluation.
Participants undergo positron emission tomography (PET) and magnetic resonance imaging (MRI)
scanning. An optional lumbar puncture (spinal tap) is also requested.
PET Scanning
PET uses small amounts of a radioactive chemical called a tracer that "labels" active areas
of the brain. The tracer used in this study is [18F]SPA-RQ. For the procedure, the subject
lies still on the scanner bed. A special mask is fitted to the head to help keep the
subject's head still during the scan so the images will be clear. A 20-minute "transmission"
scan is done before the radioactive tracer is injected to provide measures of the brain that
will help in the precise calculation of information from subsequent scans. After the tracer
is injected through a needle in the arm, pictures are taken continuously for about 2 hours.
Then, 20- to 40-minute images are taken every hour until about 5 hours after the injection.
MRI Scanning
An MRI scan is scheduled at some time within 1 year of the PET scan. MRI uses a magnetic
field and radio waves to obtain images of body tissues and organs. The subject lies still on
a table inside the tunnel-like MRI scanner. Earplugs are worn to muffle loud noises that
occur during the scanning. The maximum duration of the scan is 60 minutes.
Lumbar Puncture
Lumbar puncture is used to examine the cerebrospinal fluid (CSF) that surrounds both the
brain and the spinal cord. For this procedure, a local anesthetic is given to numb the skin
in the lower back area. A small needle is then inserted into the space between the bones in
the lower back where the CSF circulates below the spinal cord. A small amount of fluid is
collected through the needle.
Blood Draw
A blood sample is collected to generate cell lines that can be used to extract DNA (genetic
material) for gene studies and that can be frozen for future use.
Status | Completed |
Enrollment | 40 |
Est. completion date | January 2006 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | N/A and older |
Eligibility |
INCLUSION CRITERIA: PTSD Samples: Twenty subjects (age 18-65) with current PTSD, as defined by DSM-IV criteria, of any ethnicity without other significant medical conditions will be selected. Healthy Control Samples: Twenty healthy subjects (age 18-65) without a known personal or family history of psychiatric disorders in first-degree relatives will be selected. A control subject will be matched to each subject with PTSD for age, gender, and handedness, respectively. They must not be actively using illicit drugs or engaged in heavy consumption of alcohol, had no metallic implants that are ferromagnetic, and competent to sign consent forms to participate in the study. EXCLUSION CRITERIA: Patients must not have taken antidepressant or other medications likely to alter SP-NK1 receptor system. Effective medications will not be discontinued for the purpose of this study. Subjects will be excluded if they have: 1. DSM-IV Axis I diagnostic criteria other than PTSD and Major depression (All controls must not meet any of the Axis I diagnoses); 2. DSM-IV criteria for psychoactive substance abuse/dependence within six months; 3. take psychotropic medication in last 3 weeks (8 weeks for fluoxetine); 4. abnormal MRI other than minor atrophy; 5. abnormal laboratory test, including HIV test; 6. are currently pregnant or breast feeding (as documented by pregnancy testing at screening or at days of the scanning); 7. prior participation in other research protocols within the past year such that a radiation exposure together with the present study would exceed the annual limits (A total effective dose 5.0 rem in a year and a 5 rad per year to the lens of the eyes, gonads and blood-forming organs; and 15 rad annually for all other organs); 8. are unable to lay on one's back for PET/MRI scans (PET and MRI scans take approximately 5 and 1 hour, respectively); 9. any condition that increases risk for MRI (e.g., pacemaker, metallic foreign body in the eye, etc.); 10. individuals who recently donated blood; 11. serious suicidal ideation or behavior; 12. Xylocaine allergy; 13. positive HIV test. For healthy subjects, exclusion criteria b) through m) are same to those for PTSD subjects. As for item a), subjects will be excluded if they meet any current DSM-IV Axis I diagnostic criteria. |
N/A
Country | Name | City | State |
---|---|---|---|
United States | National Institute of Mental Health (NIMH) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Mental Health (NIMH) |
United States,
Breslau N, Kessler RC, Chilcoat HD, Schultz LR, Davis GC, Andreski P. Trauma and posttraumatic stress disorder in the community: the 1996 Detroit Area Survey of Trauma. Arch Gen Psychiatry. 1998 Jul;55(7):626-32. — View Citation
Davidson JR, Hughes D, Blazer DG, George LK. Post-traumatic stress disorder in the community: an epidemiological study. Psychol Med. 1991 Aug;21(3):713-21. — View Citation
Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995 Dec;52(12):1048-60. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04317820 -
Deep Brain Reorienting in Post-traumatic Stress Disorder
|
N/A | |
Completed |
NCT05112003 -
Translingual Neurostimulation for the Virtual Treatment of Post-Traumatic Stress Disorder: A Feasibility Pilot
|
N/A | |
Recruiting |
NCT04518267 -
Anger and Psychotrauma: Data From Military and Civilians
|
||
Completed |
NCT02502604 -
Cognitive Training Program for Individuals With Depression and Post-Traumatic Stress Disorder
|
N/A | |
Completed |
NCT02256566 -
Cognitive Training for Mood and Anxiety Disorders
|
N/A | |
Terminated |
NCT02234687 -
A mGlu2/3 Agonist in the Treatment of PTSD
|
Phase 1 | |
Terminated |
NCT02520726 -
PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims
|
Phase 4 | |
Completed |
NCT01738308 -
The Effects of Healing Touch on Post Operative Pediatric Patients
|
N/A | |
Completed |
NCT02213900 -
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
|
Phase 4 | |
Completed |
NCT01517711 -
Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD)
|
Phase 4 | |
Completed |
NCT01437891 -
Sentra AM® and Sentra PM® for Post-traumatic Stress Disorder (PTSD) and Gulf War Fibromyalgia (GWF)
|
N/A | |
Completed |
NCT01199107 -
Maximizing Treatment Outcome and Examining Sleep in Post-traumatic Stress Disorder (PTSD)
|
Phase 3 | |
Completed |
NCT01998100 -
Maximizing Treatment Outcome in Post-Traumatic Stress Disorder (PTSD)
|
Phase 3 | |
Completed |
NCT01231711 -
Improving Quality-of-life and Depressive Symptoms of Combat Veterans Via Internet-based Intervention
|
Phase 1 | |
Completed |
NCT00348036 -
Group Intervention for Interpersonal Trauma
|
N/A | |
Completed |
NCT00680524 -
Telephone-based Care for OEF/OIF Veterans With PTSD
|
N/A | |
Completed |
NCT00838006 -
Psychophysiologic Predictors of Post-deployment Mental Health Outcomes
|
N/A | |
Completed |
NCT00525226 -
Evaluating the Effects of Stress in Pregnancy
|
N/A | |
Completed |
NCT00183690 -
Prolonged Exposure Therapy Versus Active Psychotherapy in Treating Post-Traumatic Stress Disorder in Adolescents
|
Phase 1 | |
Completed |
NCT00158262 -
Effect of Propranolol on Preventing Posttraumatic Stress Disorder
|
Phase 4 |